US 12,286,628 B2
Diagnostic kit for metastasis and invasion of breast cancer and use of shRNA molecule for silencing expression of human LINC01614
Fangfang Tao, Zhejiang (CN); Zhiqian Zhang, Zhejiang (CN); Wenhong Liu, Zhejiang (CN); Ye Xu, Zhejiang (CN); Qingling Liu, Zhejiang (CN); and Junfeng Li, Zhejiang (CN)
Assigned to Zhejiang Chinese Medical University, Zhejiang (CN)
Filed by Zhejiang Chinese Medical University, Zhejiang (CN)
Filed on Nov. 29, 2023, as Appl. No. 18/523,743.
Application 18/523,743 is a division of application No. 17/852,380, filed on Jun. 29, 2022, granted, now 11,873,492.
Claims priority of application No. 202111494647.0 (CN), filed on Dec. 8, 2021.
Prior Publication US 2024/0124880 A1, Apr. 18, 2024
Int. Cl. C12N 15/113 (2010.01); A61P 35/04 (2006.01); C12N 15/86 (2006.01)
CPC C12N 15/1135 (2013.01) [A61P 35/04 (2018.01); C12N 15/86 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2740/15043 (2013.01)] 3 Claims
 
1. A method of silencing an expression of human LINC01614, comprising the following steps of
producing lentivirus having an shRNA molecule packaged within the lentivirus using a shRNA lentiviral expression vector, and
infecting the lentivirus to human breast cancer cells MDA-MB-231 and Hs578T,
wherein the shRNA molecule includes an shRNA-1 and/or an shRNA-2, and a sense strand nucleotide sequence of the shRNA-1 is shown as SEQ ID No. 3, an antisense strand nucleotide sequence of the shRNA-1 is shown as SEQ ID No. 4, a sense strand nucleotide sequence of the shRNA-2 is shown as SEQ ID No. 5, and an antisense strand nucleotide sequence of the shRNA-2 is shown as SEQ ID No. 6.